Local consolidative therapy may be beneficial in patients with oligometastatic non‐small cell lung cancer

Abstract

PFS was found to be significantly increased with the use of local consolidative therapy in patients with oligometastatic NSCLC with stable or responding disease after standard frontline systemic therapy. This study provides evidence that is in keeping with an increasingly common approach in patients with advanced NSCLC. Larger studies and longer follow‐up are needed to confirm an overall survival advantage and improve patient selection.